Abstracts tagged "epidemiologic methods and morbidity and mortality"

Abstract Number: 987 • 2017 ACR/ARHP Annual Meeting
Death Certificates Do Not Accurately Identify SLE Patients
Kelly Kaysen, Cristina Drenkard, Gaobin Bao and S. Sam Lim, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Mortality rates are higher in SLE patients compared to the general population, and research on SLE mortality is ongoing. The majority of mortality studies…
Abstract Number: 1885 • 2017 ACR/ARHP Annual Meeting
Epidemiology of Hospitalized Adult Onset Still’s Disease in United States
Bella Y. Mehta¹, William Briggs² and Petros Efthimiou³, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine/Mailman School of Public Health, New York, NY, ²New York Presbyterian/ Brooklyn Methodist Hospital, New York, NY, ³Medicine/Rheumatology, New York University School of Medicine/NYU Langone Health, New York, NY
Background/Purpose: There is a dearth of epidemiological studies on Adult Onset Still’s Disease (AOSD) and no consensus on its incidence and prevalence. Most studies report…
Abstract Number: 1875 • 2014 ACR/ARHP Annual Meeting
Can Allopurinol Survival Impact Reverse Depending on Patients’ Characteristics? a Propensity-Score-Based Subgroup Analysis
Na Lu¹, Hyon K. Choi², Maureen Dubreuil^3,4, Qiong Louie-Gao⁵ and Yuqing Zhang¹, ¹Boston University School of Medicine, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Several studies have reported that allopurinol use is associated with a decreased risk of death or cardiovascular outcomes. While these studies reported the overall…
Abstract Number: 2119 • 2013 ACR/ARHP Annual Meeting
Higher Mortality In Males Compared To Females Undergoing Total Knee Or Total Hip Arthroplasty: A Study Of National Time Trends, 2003-2010
Jasvinder A. Singh^1,2 and Rekha Ramachandaran³, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess the time-trends in gender differences in mortality after primary total knee and total hip arthroplasty (TKA and THA) by rural or urban…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].